0.45Open0.35Pre Close19 Volume88 Open Interest0.50Strike Price695.00Turnover602.05%IV1.39%PremiumDec 20, 2024Expiry Date0.44Intrinsic Value100Multiplier24DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.8816Delta0.1365Gamma1.44Leverage Ratio-0.0061Theta0.0001Rho1.27Eff Leverage0.0005Vega
Tempest Therapeutics Stock Discussion
13/11/2024 - 05:21
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC
Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial
Received final funding approval from NCI to move TPST-1495 into a Phas...
12/11/2024 - 21:00
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received a “Study May Proceed” letter fro...
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
No comment yet